Low-Frequency STN-DBS for Standing and Gait Initiation in Parkinson's Disease: A Double-Blinded Randomised Cross-Over Feasibility Trial.

Neurorehabil Neural RepairJun 4, 2026 (epub)
Clinical ResearchNeurologyPsychiatryOpen access

Zachary J Conway, Peter A Silburn, Thushara Perera et al.

✦ AI-curated · Sources linked

In 30 seconds

This double-blind randomized crossover trial evaluated the effects of low-frequency (60 Hz) STN-DBS on balance in 16 post-operative Parkinson's disease patients. The study found that low-frequency stimulation significantly improved balance during standing and gait initiation, while no differences were observed in clinical mobility measures or tremor management.

Key findings

  • Low-frequency STN-DBS improved balance during standing and gait initiation.
  • No differences were found in clinical measures of mobility or motor symptom severity.
  • The benefits of low-frequency stimulation were less effective for patients with significant pre-operative tremor.

Why it matters

Understanding the effects of different stimulation frequencies in STN-DBS can help optimize treatment strategies for Parkinson's disease patients, particularly in improving balance and reducing fall risk.

Source

PubMed · PMID 42240331Free full text on PubMed Central

Published in Neurorehabil Neural Repair. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.